Cytokinetics Gets A Belated Christmas Present

Aficamten hits nicely in its pivotal hypertrophic cardiomyopathy trial, and a deal will surely follow.

Until now, Cytokinetics, Inc. has had a pretty rotten year, with failures both regulatory and clinical seeing off two of its major pipeline hopes. But 2023 has ended in a blaze of glory thanks to aficamten, the cardiac myosin inhibitor that was its last remaining late-stage asset.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

01 May 2025

• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

01 May 2025

• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

01 May 2025

• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

30 Apr 2025

• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.